All In Biotech

Investigational drug · Phase 2

MT-201

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease.

Phase 2

Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

5

Any phase or sponsor naming "MT-201"

First trial start

2025

Jun 26, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "MT-201", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Inflammatory Bowel Disease (IBD)
  • Ulcerative Colitis (UC)
  • Crohn's Disease

Approved drugs for the same conditions: Crohn's disease · Ulcerative colitis · Immunology and inflammation · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "MT-201" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 4 on PubMed

Also in development for Inflammatory Bowel Disease (IBD)

  • DISC-0974Phase 22 trials

    Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia

  • HW201877Phase 21 trial

    Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. · Inflammatory Bowel Disease (IBD)

  • MT-501Phase 21 trial

    Mirador Therapeutics, Inc. · Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.